Authors
Latest:
Spotlight on Mexico: Healthcare under AMLO—One Year OnAs we near the end of the first year of Mexican president Andrés Manuel López Obrador's six-year term, Rachel Howard caught up with local expert Dr Xavier Tello to make sense of the latest changes in the healthcare system and consider what they mean for pharma manufacturers wishing to enter the Mexican market.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Access Headwinds Reach IDN Specialty Pharmacy ProgramsInsights from Partnering with IDNs: Biopharma Strategy Summit.
Latest:
Compliance in China: Key ConsiderationsDavid Simon outlines the procedures to manage anti-corruption risk that life sciences companies should consider before doing business in China.
Latest:
Healthcare Reform in Ukraine Opens New Horizons for InvestorsAs the Ukranian healthcare market opens up to more public and private competition, it will become more attractive for investors - both Ukrainian and foreign, write Lana Sinichkina and Anna Zorya.
Latest:
Listening Is the Key to Becoming More Than Just Better MarketersBut how much better would our creative be if we took the time to really listen to what our clients are saying – and what they are not saying – rather than reading between the lines of an RFP?
Latest:
CRO Trends 2018Improving the productivity of sponsors’ clinical development processes will continue to be a primary driver of outsourcing in 2018, writes Nuala Murphy.
Latest:
Three Facets of Trust in Artificial IntelligenceAre the technologies and assumptions at the heart of healthcare AI trustworthy?
Latest:
The PD-1 Race in China Heats UpBoth foreign and domestic pharmas are in a race to bring PD-1/PD-L1 inhibitors into China, writes Jin Zhang.
Latest:
How Tax Reform Will Affect the Pharmaceutical IndustryThis article examines the key ways the new tax bill will impact the pharmaceutical industry.
Latest:
How to Build a Strategic Digital Health Function within BiopharmaKey takeaways on digital health from the 2021 JP Morgan Healthcare conference.
Latest:
Why a Data Health Check May Be the Best Medicine for Pharmaceutical Regulatory ComplianceAdhering to new compliance legislation such as Identification of Medicinal Products (IDMP) can bring a pharma company benefits as well as challenges, writes Darren Cooper.
Latest:
Delivering Value from Data AnalyticsFor companies that overcome the challenges, there is tremendous opportunity to drive sustainable growth through technology and analytics-driven business innovation, writes Vita Cassese.
Latest:
The Personalized Genetic Profile: It’s Time to AlignInnovations in consumer genetic health are rapidly advancing-and pharma commercial thinking needs to catch up.
Latest:
The Personalized Genetic Profile: It’s Time to AlignInnovations in consumer genetic health are rapidly advancing-and pharma commercial thinking needs to catch up.
Latest:
Pricing Turning Point: The Case for Innovating Pharma’s ModelDrawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.
Latest:
Pricing Turning Point: The Case for Innovating Pharma’s ModelDrawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.
Latest:
Pharma Tech Trends for Today and TomorrowAdTech (Advertising Technology) and AI/ML (Artificial Intelligence/Machine Learning) are playing significant roles in transforming the healthcare industry, particularly in areas like digital marketing and clinical trials. Let's explore each area in more detail.
Latest:
Shining a Light on Supply Chain VisibilitySteve Cottrell assesses the risks of lapses in pharma's supply chain visibility and outlines what can be done to minimize them
Latest:
Transparent and Relevant Evaluations of Value: An Active Role for PharmaThe biopharma industry should embrace the developments about value assessment in the US and take a leading role in defining and demonstrating what can be considered credible and relevant cost-effectiveness studies, write Ross Maclean and Jeroen Jansen.
